文献
J-GLOBAL ID:202002264107836295
整理番号:20A2158571
2型糖尿病の日本人におけるインスリングラルギン100単位/mLおよびリキシセナチド(iGlarLixi)の固定比併用の利点: LixiLan JP第3相試験のサブグループおよび時間-対照分析【JST・京大機械翻訳】
Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials
著者 (11件):
Terauchi Yasuo
(Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokahama, Japan)
,
Yabe Daisuke
(Department of Diabetes and Endocrinology, Gifu University Graduate School of Medicine, Gifu, Japan)
,
Yabe Daisuke
(Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka, Japan)
,
Yabe Daisuke
(Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, Kobe, Japan)
,
Kaneto Hideaki
(Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan)
,
Amano Atsushi
(Research & Development, Sanofi K.K., Tokyo, Japan)
,
Baxter Mike
(Primary Care, Medical, Sanofi, Guildford, UK)
,
Baxter Mike
(University of Swansea, Swansea, UK)
,
Watanabe Daisuke
(Research & Development, Sanofi K.K., Tokyo, Japan)
,
Watada Hirotaka
(Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan)
,
Inagaki Nobuya
(Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan)
資料名:
Diabetes Obesity & Metabolism
(Diabetes Obesity & Metabolism)
巻:
22 Suppl S4
ページ:
35-47
発行年:
2020年
JST資料番号:
W2549A
ISSN:
1462-8902
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)